astellas pharma inc
(4503:Tokyo Stock Exchange)
Sef P. Kurstjens M.D., Ph.D.
Chief Medical Officer and President of Global Development,Astellas Pharma Inc.
|Age||Total Calculated Compensation||This person is connected to 61 board members in 1 different organizations across 3 different industries.|
See Board Relationships
Dr. Sef P. Kurstjens, M.D., Ph.D. serves as Chief Medical Officer at Astellas Pharma Inc. Dr. Kurstjens has been the President of Astellas Pharma Global Development, Inc. since October 2013. Dr. Kurstjens serves as Chief Medical Officer of Astellas Pharma, Inc. Dr. Kurstjens served as the President and the Chief Executive Officer at Agensys, Inc. since November 2010. Dr. Kurstjens served as the Senior Vice President, Chief Medical Officer and Head, Global Drug Development ...
2-5-1, Nihonbashi-HonchoPhone: 81 3 3244 3000
Tokyo, -- 103-8411
Board Members Memberships*
Wits Medical School
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
|Vincent A. Forlenza||Chairman, Chief Executive Officer and President|
Becton, Dickinson and Company
|José E. Almeida||Chairman and Chief Executive Officer|
Baxter International Inc.
|Joseph C. Papa||Chairman of the Board and Chief Executive Officer|
Valeant Pharmaceuticals International, Inc.
|Jean-Pierre Clamadieu||Chief Executive Officer, Director and Member of Finance Committee|
|Christophe Weber||Chief Executive Officer, President and Representative Director|
Takeda Pharmaceutical Company Limited
|¥495.0M||Compensation as of Fiscal Year 2016.|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.